VYGR Quote, Financials, Valuation and Earnings

Design Therapeutics has a net margin of -36.72% compared to Voyager Therapeutics's net margin of --. Voyager Therapeutics's return on equity of 9.12% beat Design Therapeutics's return on equity of --.

Voyager Therapeutics has a consensus price target of $17.10, signalling upside risk potential of 213.76%. On the other hand Design Therapeutics has an analysts' consensus of -- which suggests that it could grow by 54.87%. Given that Voyager Therapeutics has higher upside potential than Design Therapeutics, analysts believe Voyager Therapeutics is more attractive than Design Therapeutics.

Voyager Therapeutics has a beta of 0.929, which suggesting that the stock is 7.053% less volatile than S&P 500. In comparison Design Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Design Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Design Therapeutics pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $24.6M, which are larger than Design Therapeutics quarterly revenues of --. Voyager Therapeutics's net income of -$9M is higher than Design Therapeutics's net income of -$13M. Notably, Voyager Therapeutics's price-to-earnings ratio is 8.38x while Design Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 1.86x versus -- for Design Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics has a net margin of -36.72% compared to Voyager Therapeutics's net margin of -54.2%. Voyager Therapeutics's return on equity of 9.12% beat PTC Therapeutics's return on equity of --.

Voyager Therapeutics has a consensus price target of $17.10, signalling upside risk potential of 213.76%. On the other hand PTC Therapeutics has an analysts' consensus of $58.36 which suggests that it could grow by 32.81%. Given that Voyager Therapeutics has higher upside potential than PTC Therapeutics, analysts believe Voyager Therapeutics is more attractive than PTC Therapeutics.

Voyager Therapeutics has a beta of 0.929, which suggesting that the stock is 7.053% less volatile than S&P 500. In comparison PTC Therapeutics has a beta of 0.619, suggesting its less volatile than the S&P 500 by 38.129%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. PTC Therapeutics pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $24.6M, which are smaller than PTC Therapeutics quarterly revenues of $196.8M. Voyager Therapeutics's net income of -$9M is higher than PTC Therapeutics's net income of -$106.7M. Notably, Voyager Therapeutics's price-to-earnings ratio is 8.38x while PTC Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 1.86x versus 3.73x for PTC Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals has a net margin of -36.72% compared to Voyager Therapeutics's net margin of -131.25%. Voyager Therapeutics's return on equity of 9.12% beat Rhythm Pharmaceuticals's return on equity of -208.96%.

Voyager Therapeutics has a consensus price target of $17.10, signalling upside risk potential of 213.76%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $73.18 which suggests that it could grow by 30.29%. Given that Voyager Therapeutics has higher upside potential than Rhythm Pharmaceuticals, analysts believe Voyager Therapeutics is more attractive than Rhythm Pharmaceuticals.

Voyager Therapeutics has a beta of 0.929, which suggesting that the stock is 7.053% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.165, suggesting its more volatile than the S&P 500 by 116.542%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $24.6M, which are smaller than Rhythm Pharmaceuticals quarterly revenues of $33.3M. Voyager Therapeutics's net income of -$9M is higher than Rhythm Pharmaceuticals's net income of -$43.6M. Notably, Voyager Therapeutics's price-to-earnings ratio is 8.38x while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 1.86x versus 30.15x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -36.72% compared to Voyager Therapeutics's net margin of 7.2%. Voyager Therapeutics's return on equity of 9.12% beat Sarepta Therapeutics's return on equity of 12.48%.

Voyager Therapeutics has a consensus price target of $17.10, signalling upside risk potential of 213.76%. On the other hand Sarepta Therapeutics has an analysts' consensus of $184.91 which suggests that it could grow by 48.18%. Given that Voyager Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Voyager Therapeutics is more attractive than Sarepta Therapeutics.

Voyager Therapeutics has a beta of 0.929, which suggesting that the stock is 7.053% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.770, suggesting its less volatile than the S&P 500 by 22.964%.

Voyager Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Voyager Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Voyager Therapeutics quarterly revenues are $24.6M, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Voyager Therapeutics's net income of -$9M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Voyager Therapeutics's price-to-earnings ratio is 8.38x while Sarepta Therapeutics's PE ratio is 81.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Voyager Therapeutics is 1.86x versus 7.65x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.